Recombinant Human PD-L1 Protein(Sumo Tag)
Recombinant Human PD-L1 Protein(Sumo Tag) supplied by Elabscience with collaborator-provided technical specifications. Read more ›
["43 kDa"]Product Description
PD-L1 is the stated recombinant protein target for this Elabscience product. The listing uses collaborator-supplied specifications to support research-use-only protein selection through ABMIUM.
Protein profile: reactive species/source: Human; expression system: E.coli; physical form: Lyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5% Mannitol.; tag: Human ,PD-L1 ,Recombinant Proteins; predicted molecular weight: 37.1 kDa.
Quality and formulation: purity: > 85% as determined by reducing SDS-PAGE.; endotoxin: < 10 EU/mg of the protein as determined by the LAL method.
Sequence coverage: 37.1 kDa.
Database references: UniProt: Q9NZQ7 | NCBI Gene: 29126 | Gene symbol: PD-L1.
Research Use Only.
Key Facts
| Target | PD-L1 |
| Also known as | PDL, B7H, PD-L, PD1L, Programmed cell death 1 ligand, PDCD1L, PDCD1LG, B7-H, B7H1, PDL1, PD-L1, PDCD1L1, PDCD1LG1, CD274, B7-H1, B7 homolog 1, CD274 molecule, PDCD1 ligand 1, Programmed death ligand 1, PD1L1, Programmed cell death 1 ligand 1, PDL1, PD-L1, B7-H, B7H1, CD274 molecule, PDCD1L1, PDCD1LG1, B7 H, B7 H1, CD 274, CD274 antigen, MGC142294, MGC142296, OTTHUMP00000021029, PD L1, PDL 1, RGD1566211 |
| Species reactivity | Human |
| Purity | > 85% as determined by reducing SDS-PAGE. |
| Form / buffer | Lyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5% Mannitol. |
| Shelf life | 12 months |
| Research area | Cancer, Immunology, Signal Transduction |
| BIOACTIVITY | BINDING | CELL-BASED | IN VIVO | ELISA CAPTURE | |
|---|---|---|---|---|---|
| Human |
Specifications
Storage & Stability
Compliance & Certifications
Manufactured under ISO 9001:2015 quality management standards.
Manufactured under ISO 14001:2015 quality management standards.
Manufactured under ISO 45001:2018 quality management standards.
Not intended for diagnostic or therapeutic use.
Substance does not appear on the SVHC candidate list.